targeted therapies

Why Are Most Chemo Drugs Synthetic Rather Than Biogenic?

Published September 28, 2013

Question by yug_zohoth: Why are most chemo drugs synthetic rather than biogenic?
I’m curious to know why cancer chemotherapy still relies on the usage and further “drug discovery” of synthetic drugs which are injected into the bloodstream and thus affect… Continue reading →

Strategies to Increase Drug Penetration in Solid Tumors.

Published July 31, 2013

Strategies to increase drug penetration in solid tumors.

Front Oncol. 2013; 3: 193
Choi IK, Strauss R, Richter M, Yun CO, Lieber A

Despite significant improvement in modalities for treatment of cancer that led to a longer survival period,… Continue reading →

Mechanisms of Drug-Induced Proarrhythmia in Clinical Practice.

Published July 13, 2013

Mechanisms of drug-induced proarrhythmia in clinical practice.

World J Cardiol. 2013 Jun 26; 5(6): 175-185
Konstantopoulou A, Tsikrikas S, Asvestas D, Korantzopoulos P, Letsas KP

Drug-induced proarrhythmia represents a great challenge for those involved in the development of novel… Continue reading →

Combined Radio- and Chemotherapy for Non-Small Cell Lung Cancer: Systematic Review of Landmark Studies Based on Acquired Citations.

Published July 13, 2013

Combined Radio- and Chemotherapy for Non-Small Cell Lung Cancer: Systematic Review of Landmark Studies Based on Acquired Citations.

Front Oncol. 2013; 3: 176
Nieder C, Pawinski A, Andratschke NH

The important role of combined chemoradiation for several groups of… Continue reading →

IL-23R Is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer.

Published June 28, 2013

IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer.

Front Oncol. 2013; 3: 162
Baird AM, Dockry E, Daly A, Stack E, Doherty DG, O’Byrne KJ, Gray SG

The Interleukin-23 (IL-23)/IL-23R signaling axis is an… Continue reading →

A Review of Targeted Therapies Evaluated by the Pediatric Preclinical Testing Program for Osteosarcoma.

Published June 12, 2013

A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.

Front Oncol. 2013; 3: 132
Sampson VB, Gorlick R, Kamara D, Anders Kolb E

Osteosarcoma, the most common malignant bone tumor of childhood, is a… Continue reading →

Overview of Cancer Stem Cells (CSCs) and Mechanisms of Their Regulation: Implications for Cancer Therapy.

Published June 9, 2013

Overview of Cancer Stem Cells (CSCs) and Mechanisms of Their Regulation: Implications for Cancer Therapy.

Curr Protoc Pharmacol. 2013 Jun; Chapter 14: Unit14.25
Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH

The identification of small subpopulations of… Continue reading →

Self-Care Strategies to Relieve Fatigue in Patients Receiving Radiation Therapy.

Published May 31, 2013

Self-care strategies to relieve fatigue in patients receiving radiation therapy.

Clin J Oncol Nurs. 2013 Jun 1; 17(3): 319-24
Erickson JM, Spurlock LK, Kramer JC, Davis MA

Despite advances in symptom management, patients commonly experience fatigue during radiation therapy… Continue reading →

The Role of Tumor Tissue Architecture in Treatment Penetration and Efficacy: An Integrative Study.

Published May 31, 2013

The role of tumor tissue architecture in treatment penetration and efficacy: an integrative study.

Front Oncol. 2013; 3: 111
Rejniak KA, Estrella V, Chen T, Cohen AS, Lloyd MC, Morse DL

Despite the great progress that has been made… Continue reading →

Deubiquitylating Enzymes and DNA Damage Response Pathways.

Published May 30, 2013

Deubiquitylating Enzymes and DNA Damage Response Pathways.

Cell Biochem Biophys. 2013 May 28;
Jacq X, Kemp M, Martin NM, Jackson SP

Covalent post-translational modification of proteins by ubiquitin and ubiquitin-like factors has emerged as a general mechanism to regulate… Continue reading →